ANI Pharmaceuticals stock falls despite strong guidance.

ANI Pharmaceuticals stock falls despite strong guidance. The pharmaceutical company issued solid FY26 guidance projecting 15% non-GAAP EPS growth, driven by momentum in its Cortrophin Gel product. However, shares have declined roughly 25% from their September 2025 all-time high of $99.50, even following an impressive fourth quarter report. Cortrophin Gel is expected to represent 52% of FY26 revenue, creating some concentration risk but offset by patent protection and complex formulation barriers. The company maintains a solid balance sheet supporting continued investments in rare disease expansion and plans for 10 to 15 annual generic drug launches. Analysts view the pullback as potentially creating an attractive entry point for investors seeking exposure to the specialty pharmaceutical sector.